Cargando…
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?
Coronavirus disease 2019 (COVID‐19) is often associated with interstitial pneumonia. However, there is insufficient knowledge on the presence of autoimmune serological markers in patients with COVID‐19. We analyzed the presence and role of autoantibodies in patients with COVID‐19‐associated pneumoni...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536986/ https://www.ncbi.nlm.nih.gov/pubmed/32989903 http://dx.doi.org/10.1111/cts.12908 |
_version_ | 1783590635557617664 |
---|---|
author | Pascolini, Simona Vannini, Antonio Deleonardi, Gaia Ciordinik, Michele Sensoli, Annamaria Carletti, Ilaria Veronesi, Lorenza Ricci, Chiara Pronesti, Alessia Mazzanti, Laura Grondona, Ana Silvestri, Tania Zanuso, Stefano Mazzolini, Marcello Lalanne, Claudine Quarneti, Chiara Fusconi, Marco Giostra, Fabrizio Granito, Alessandro Muratori, Luigi Lenzi, Marco Muratori, Paolo |
author_facet | Pascolini, Simona Vannini, Antonio Deleonardi, Gaia Ciordinik, Michele Sensoli, Annamaria Carletti, Ilaria Veronesi, Lorenza Ricci, Chiara Pronesti, Alessia Mazzanti, Laura Grondona, Ana Silvestri, Tania Zanuso, Stefano Mazzolini, Marcello Lalanne, Claudine Quarneti, Chiara Fusconi, Marco Giostra, Fabrizio Granito, Alessandro Muratori, Luigi Lenzi, Marco Muratori, Paolo |
author_sort | Pascolini, Simona |
collection | PubMed |
description | Coronavirus disease 2019 (COVID‐19) is often associated with interstitial pneumonia. However, there is insufficient knowledge on the presence of autoimmune serological markers in patients with COVID‐19. We analyzed the presence and role of autoantibodies in patients with COVID‐19‐associated pneumonia. We prospectively studied 33 consecutive patients with COVID‐19, 31 (94%) of whom had interstitial pneumonia, and 25 age‐matched and sex‐matched patients with fever and/or pneumonia with etiologies other than COVID‐19 as the pathological control group. All patients were tested for the presence of antinuclear antibodies (ANAs), anti‐antiphospholipid antibodies, and anti‐cytoplasmic neutrophil antibodies (ANCAs). Clinical, biochemical, and radiological parameters were also collected. Fifteen of 33 patients (45%) tested positive for at least one autoantibody, including 11 who tested positive for ANAs (33%), 8 who tested positive for anti‐cardiolipin antibodies (immunoglobulin (Ig)G and/or IgM; 24%), and 3 who tested positive for anti‐β2‐glycoprotein antibodies (IgG and/or IgM; 9%). ANCA reactivity was not detected in any patient. Patients that tested positive for auto‐antibodies had a significantly more severe prognosis than other patients did: 6 of 15 patients (40%) with auto‐antibodies died due to COVID‐19 complications during hospitalization, whereas only 1 of 18 patients (5.5%) who did not have auto‐antibodies died (P = 0.03). Patients with poor prognosis (death due to COVID‐19 complications) had a significantly higher respiratory rate at admission (23 breaths per minute vs. 17 breaths per minute; P = 0.03) and a higher frequency of auto‐antibodies (86% vs. 27%; P = 0.008). In conclusion, auto‐antibodies are frequently detected in patients with COVID‐19 possibly reflecting a pathogenetic role of immune dysregulation. However, given the small number of patients, the association of auto‐antibodies with an unfavorable prognosis requires further multicenter studies. |
format | Online Article Text |
id | pubmed-7536986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75369862020-10-07 COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? Pascolini, Simona Vannini, Antonio Deleonardi, Gaia Ciordinik, Michele Sensoli, Annamaria Carletti, Ilaria Veronesi, Lorenza Ricci, Chiara Pronesti, Alessia Mazzanti, Laura Grondona, Ana Silvestri, Tania Zanuso, Stefano Mazzolini, Marcello Lalanne, Claudine Quarneti, Chiara Fusconi, Marco Giostra, Fabrizio Granito, Alessandro Muratori, Luigi Lenzi, Marco Muratori, Paolo Clin Transl Sci Research Coronavirus disease 2019 (COVID‐19) is often associated with interstitial pneumonia. However, there is insufficient knowledge on the presence of autoimmune serological markers in patients with COVID‐19. We analyzed the presence and role of autoantibodies in patients with COVID‐19‐associated pneumonia. We prospectively studied 33 consecutive patients with COVID‐19, 31 (94%) of whom had interstitial pneumonia, and 25 age‐matched and sex‐matched patients with fever and/or pneumonia with etiologies other than COVID‐19 as the pathological control group. All patients were tested for the presence of antinuclear antibodies (ANAs), anti‐antiphospholipid antibodies, and anti‐cytoplasmic neutrophil antibodies (ANCAs). Clinical, biochemical, and radiological parameters were also collected. Fifteen of 33 patients (45%) tested positive for at least one autoantibody, including 11 who tested positive for ANAs (33%), 8 who tested positive for anti‐cardiolipin antibodies (immunoglobulin (Ig)G and/or IgM; 24%), and 3 who tested positive for anti‐β2‐glycoprotein antibodies (IgG and/or IgM; 9%). ANCA reactivity was not detected in any patient. Patients that tested positive for auto‐antibodies had a significantly more severe prognosis than other patients did: 6 of 15 patients (40%) with auto‐antibodies died due to COVID‐19 complications during hospitalization, whereas only 1 of 18 patients (5.5%) who did not have auto‐antibodies died (P = 0.03). Patients with poor prognosis (death due to COVID‐19 complications) had a significantly higher respiratory rate at admission (23 breaths per minute vs. 17 breaths per minute; P = 0.03) and a higher frequency of auto‐antibodies (86% vs. 27%; P = 0.008). In conclusion, auto‐antibodies are frequently detected in patients with COVID‐19 possibly reflecting a pathogenetic role of immune dysregulation. However, given the small number of patients, the association of auto‐antibodies with an unfavorable prognosis requires further multicenter studies. John Wiley and Sons Inc. 2021-01-20 2021-03 /pmc/articles/PMC7536986/ /pubmed/32989903 http://dx.doi.org/10.1111/cts.12908 Text en © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Pascolini, Simona Vannini, Antonio Deleonardi, Gaia Ciordinik, Michele Sensoli, Annamaria Carletti, Ilaria Veronesi, Lorenza Ricci, Chiara Pronesti, Alessia Mazzanti, Laura Grondona, Ana Silvestri, Tania Zanuso, Stefano Mazzolini, Marcello Lalanne, Claudine Quarneti, Chiara Fusconi, Marco Giostra, Fabrizio Granito, Alessandro Muratori, Luigi Lenzi, Marco Muratori, Paolo COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? |
title | COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? |
title_full | COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? |
title_fullStr | COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? |
title_full_unstemmed | COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? |
title_short | COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful? |
title_sort | covid‐19 and immunological dysregulation: can autoantibodies be useful? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536986/ https://www.ncbi.nlm.nih.gov/pubmed/32989903 http://dx.doi.org/10.1111/cts.12908 |
work_keys_str_mv | AT pascolinisimona covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT vanniniantonio covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT deleonardigaia covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT ciordinikmichele covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT sensoliannamaria covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT carlettiilaria covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT veronesilorenza covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT riccichiara covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT pronestialessia covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT mazzantilaura covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT grondonaana covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT silvestritania covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT zanusostefano covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT mazzolinimarcello covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT lalanneclaudine covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT quarnetichiara covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT fusconimarco covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT giostrafabrizio covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT granitoalessandro covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT muratoriluigi covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT lenzimarco covid19andimmunologicaldysregulationcanautoantibodiesbeuseful AT muratoripaolo covid19andimmunologicaldysregulationcanautoantibodiesbeuseful |